News Updates
More Articles
- Vaccine makers to produce human bird flu vaccines
- Automated stem cell production system undergoes testing
- FDA OKs Novartis' low-grade glioma drug combo for kids
- Grants support biomanufacturing partnerships in Australia
- Takeda Oncology aims for more partnership to grow its pipelines
Pfizer wins stake to acquire Seagen with $43B bid
Pfizer has prevailed in the bidding war to acquire antibody-drug conjugate developer Seagen via its $43 billion bid, a deal that is expected to be finalized either late this year or by early 2024. Seagen's ADC tech, combined with Pfizer's size and strength, will help "advance the battle against cancer," according to Pfizer CEO Albert Bourla. BioSpace (San Francisco) (3/13)
Read full article now.
×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!